Recombinant Human Muscarinic acetylcholine receptor M1 (CHRM1)

What is the Muscarinic Acetylcholine Receptor M1 (CHRM1) and what is its primary function in the nervous system?

CHRM1 is a G protein-coupled receptor that plays crucial roles in cholinergic neurotransmission. It primarily couples to Gαq/11 proteins to initiate signal transduction pathways, particularly in cortical neurons . CHRM1 is essential for modulating cortical-subcortical communication and is significantly involved in working memory processes that require cortical and hippocampal engagement . Recent studies have also revealed a previously unknown association between CHRM1 and mitochondrial function, suggesting its involvement in cellular energetics beyond traditional receptor signaling roles .

How is CHRM1 typically expressed in the human brain?

CHRM1 shows distinct expression patterns across various brain regions. It is prominently expressed in the:

• Dorsolateral prefrontal cortex (Brodmann area 9)

• Cortical laminae V, specifically in pyramidal neurons that facilitate cortical-subcortical communication

• Hippocampus

• Peripheral nervous system, including dorsal root ganglion (DRG) neurons

The receptor's expression is significantly altered in neurological conditions, with markedly lower levels observed in patients with Alzheimer's disease and a subpopulation of patients with schizophrenia .

What methods are commonly used to detect and quantify CHRM1 expression?

Several complementary approaches are used to study CHRM1 expression:

When analyzing CHRM1 in human tissues, it's important to note that antibody reactivity patterns may differ between human and mouse tissues, potentially due to species-specific post-translational modifications .

What is the relationship between CHRM1 and mitochondrial function?

Recent evidence has established a direct relationship between CHRM1 and mitochondrial function:

• Fluorescence imaging reveals colocalization and comigration of N-terminal GFP-tagged CHRM1 with mitochondria in neurons

• CHRM1 protein is significantly enriched (2-3 fold) in mitochondrial fractions compared to total tissue lysates

• Loss of CHRM1 leads to significant reduction in mitochondrial respiration (oxygen consumption) and disruption of mitochondrial ultrastructure

• CHRM1 deletion causes reduced oligomerization of ATP synthase (complex V) and impaired assembly of respiratory chain supercomplexes (respirasomes)

• Conversely, overexpression of CHRM1 in cells lacking the native receptor increases complex V oligomerization and respirasome assembly, enhancing respiration

These findings indicate that CHRM1 plays a previously unrecognized role in maintaining mitochondrial structural and functional integrity, potentially explaining some of the energetic deficits observed in disorders with reduced CHRM1 expression .

How does CHRM1 expression change in neurodegenerative diseases?

Significant alterations in CHRM1 expression have been documented in neurodegenerative conditions:

In Alzheimer's disease:

• Significantly lower CHRM1 protein levels in cortical tissues of AD patients

• Reduced CHRM1 levels correlate with decreased patient survival

• The connection between CHRM1 loss and mitochondrial dysfunction provides a potential mechanistic link to AD pathogenesis

In schizophrenia:

• A subpopulation of patients ("muscarinic receptor-deficit schizophrenia" or MRDS) shows 60-80% reduction in cortical CHRM1 binding

• This reduction specifically affects CHRM1 but not other muscarinic receptor subtypes like CHRM2/CHRM3 or CHRM4

• Patients with schizophrenia show loss of CHRM1-positive pyramidal neurons in cortical laminae V, crucial for cortical-subcortical communication

These findings suggest that targeting CHRM1 might represent a therapeutic approach for both conditions, though through potentially different mechanisms .

What structural and functional changes occur in mitochondria when CHRM1 is deleted?

CHRM1 deletion causes dramatic mitochondrial abnormalities at both structural and functional levels:

Structural changes:

• Disruption and loss of cristae in 87% of neurons in CHRM1-/- dorsal root ganglia

• Altered tinctorial properties of cortical neurons with significant increase in dark neurons (85% in CHRM1-/- vs. 2% in wild-type)

• Impaired supramolecular assembly of respiratory chain complexes

Functional changes:

• Significantly reduced cortical mitochondrial respiration

• Decreased proton leak across the inner mitochondrial membrane

• Altered respiratory control ratio (RCR), though this appears to result from decreased proton leak rather than improved efficiency

• Impaired electron flow through the respiratory chain complexes

These findings reveal that CHRM1 is essential for maintaining proper mitochondrial structure and function, with its loss leading to severe mitochondrial dysfunction that may contribute to neuronal impairment .

How do changes in CHRM1-G protein coupling efficiency contribute to schizophrenia pathophysiology?

A fascinating compensatory mechanism has been identified in muscarinic receptor-deficit schizophrenia (MRDS) patients:

• Despite 60-80% reduction in CHRM1 expression, the efficacy of CHRM1-Gαq/11 coupling is actually increased

• This represents an adaptive change in receptor-G protein coupling efficiency

• The potency of CHRM agonists (measured by pEC₅₀) is decreased in MRDS, but the maximal signaling response is preserved or enhanced

• Both orthosterically and allosterically acting CHRM agonists can still stimulate receptor-driven functional responses in membranes from MRDS patients

This compensatory upregulation of coupling efficiency may represent an attempt to maintain cholinergic signaling despite reduced receptor availability. This finding has important implications for therapeutic approaches, suggesting that targeting receptor coupling mechanisms rather than simply increasing receptor expression might be beneficial in this subgroup of patients .

What mechanisms explain the relationship between CHRM1 loss and mitochondrial dysfunction in neurodegenerative disorders?

The relationship between CHRM1 and mitochondrial function involves several interdependent mechanisms:

• Organization of respiratory complexes:

  • CHRM1 loss reduces oligomerization of ATP synthase (complex V)

  • CHRM1 deletion impairs the formation of respirasomes (supercomplexes of complexes I-IV)

  • These organizational changes directly impact electron transport efficiency

• Mitochondrial membrane integrity:

  • CHRM1-/- mitochondria show significant ultrastructural defects, particularly cristae disruption

  • These structural changes likely affect membrane potential and proton gradient

• Respiratory chain function:

  • Oxygen consumption rates are significantly reduced in CHRM1-/- cortical mitochondria

  • Complex I-IV-mediated respiration is particularly affected

  • State 3 (ADP-stimulated) respiration is significantly diminished

The demonstration that overexpression of CHRM1 in cells lacking the native receptor can rescue these defects provides strong evidence for a direct causal relationship between CHRM1 and mitochondrial function, rather than secondary effects .

What behavioral and cognitive effects are observed in CHRM1 knockout models?

CHRM1 knockout mice show a specific pattern of cognitive and behavioral effects:

• No deficits in sensory-motor gating, nociception, motor coordination, or anxiety-related behavior

• Preserved hippocampal learning and memory in standard tests

• Severe impairment in non-matching-to-sample working memory tasks that require cortical-hippocampal coordination

This selective pattern of deficits aligns with the expression pattern of CHRM1 in cortical laminae V pyramidal neurons that facilitate cortical-subcortical communication . The specificity of the cognitive impairment in working memory without broader deficits in other domains makes CHRM1 knockout mice particularly valuable for studying aspects of cognitive dysfunction relevant to schizophrenia and Alzheimer's disease .

How can mitochondrial fractions enriched for CHRM1 be isolated for functional studies?

The isolation and enrichment of CHRM1-containing mitochondria requires specialized techniques:

• Preparation of enriched mitochondrial fractions:

  • Isolation protocols should yield both intact isolated mitochondria and membrane-bound mitochondria present in excitatory presynaptic dendritic terminals

  • Verification of mitochondrial enrichment using markers like Voltage Dependent Anion Channel (Vdac1)

  • Quantification shows 2-3 fold enrichment of both mitochondrial markers and CHRM1 in these fractions

• Characterization and quality control:

  • Transmission electron microscopy (TEM) to verify the structural integrity of isolated mitochondria

  • Identification of synaptic terminals by the presence of synaptic vesicles adjacent to synaptic clefts

  • The fraction should contain both presynaptic terminals (identified by abundant synaptic vesicles) and postsynaptic terminals (less electron-dense with fewer vesicles)

This approach enables the study of CHRM1 in its native mitochondrial environment, allowing for functional assays that would not be possible with recombinant systems alone .

What assays are most effective for measuring CHRM1-mediated mitochondrial function?

Several complementary assays can effectively measure the impact of CHRM1 on mitochondrial function:

• Oxygen consumption rate (OCR) measurements:

  • Coupling assays to evaluate respiration states (basal, state 3, state 4, and maximal)

  • Electron flow assays to assess function of specific respiratory chain complexes

  • Measurement in point-to-point mode to capture dynamic changes and middle-point mode for statistical comparisons

• Analysis of respiratory chain complex assembly:

  • Blue native polyacrylamide gel electrophoresis to separate intact respiratory complexes and supercomplexes

  • Immunoblotting with antibodies specific to different complex subunits (Ndufb8, Sdhb, Uqcrc2, Mtco1, Atp5a)

  • Quantification of high molecular weight (≥720 kDa) complexes and subcomplexes (100-500 kDa)

• Respiratory parameters calculation:

  • Respiratory Control Ratio (RCR) = State 3 respiration / State 4 respiration

  • Non-mitochondrial respiration subtraction to calculate true mitochondrial oxygen consumption

These methods have successfully demonstrated significant functional deficits in cortical mitochondria from CHRM1 knockout mice and shown that CHRM1 overexpression can rescue these defects .

How can recombinant CHRM1 be effectively tagged for localization studies?

Effective fluorescent tagging of CHRM1 requires careful design to maintain receptor functionality:

• N-terminal GFP tagging has been successfully used for visualizing CHRM1 localization and trafficking

• This approach preserves the receptor's ability to colocalize and comigrate with mitochondria in neurons

• For mitochondrial colocalization studies, combining GFP-tagged CHRM1 with mitochondrial localization signal peptide-tagged RFP provides effective dual visualization

• Time-lapse confocal imaging of these tagged constructs enables tracking of dynamic interactions between CHRM1 and mitochondria in living neurons

While the search results don't specifically address potential functional impairments from tagging, the successful localization studies suggest that N-terminal fluorescent protein tagging preserves at least some aspects of CHRM1 function and trafficking .

What methods are optimal for studying CHRM1 signaling in ex vivo preparations?

The [³⁵S]-GTP-γ-S-Gαq/11 immunocapture method has proven effective for studying CHRM1 signaling in human tissue:

• Assay preparation:

  • Membrane preparation from post-mortem human cortical tissue (specifically Brodmann area 9)

  • Treatment with CHRM agonists (oxotremorine-M) or CHRM1-selective agonists (AC-42)

  • Measurement of G-protein activation through [³⁵S]-GTP-γ-S binding to Gαq/11

• Data analysis approach:

  • Concentration-response curves fitted by non-linear regression analysis with variable slope

  • Assessment of key parameters:

    • Signal window (counts per minute)

    • Hill slope (measure of cooperativity)

    • pEC₅₀ (measure of potency)

  • Analysis of covariance with age as a covariate for binding-over-basal measurements

  • Pearson product-moment correlations to analyze relationships between experimental and clinical parameters

This method has successfully identified altered signaling properties in schizophrenia patients, demonstrating increased efficacy of CHRM1-Gαq/11 coupling despite reduced receptor expression .

How might CHRM1-targeting approaches differ between Alzheimer's disease and schizophrenia?

Based on current understanding, therapeutic strategies targeting CHRM1 would need distinct approaches for each condition:

For Alzheimer's disease:

• Focus on preserving or increasing CHRM1 expression levels, which are reduced in AD cortices

• Target mitochondrial function, given the established connection between CHRM1 loss and mitochondrial dysfunction

• Consider approaches that could stabilize the interaction between CHRM1 and mitochondria to maintain energy production

For schizophrenia (particularly MRDS):

• Address the paradoxical increase in CHRM1-G protein coupling efficiency despite reduced receptor numbers

• Consider compounds that might normalize this compensatory mechanism rather than simply increasing receptor expression

• Target downstream signaling pathways that may be dysregulated due to altered coupling efficiency

Both conditions would benefit from approaches that consider CHRM1's role in gene expression regulation, as CHRM1-mediated changes in gene expression are relevant to both pathologies .

What are the current challenges in developing CHRM1-targeted therapeutics?

Several challenges need to be addressed in CHRM1-targeted therapeutic development:

• Heterogeneity in receptor dysfunction:

  • Subpopulation-specific alterations (e.g., MRDS in schizophrenia)

  • Variable expression changes across brain regions

  • Potential differences in peripheral versus central nervous system effects

• Technical challenges:

  • Species differences in antibody reactivity and post-translational modifications

  • Difficulty in reliably measuring receptor function in patient tissues

  • Need for methods that can distinguish CHRM1 from other muscarinic receptor subtypes

• Complex functional considerations:

  • Dual role in traditional G-protein signaling and mitochondrial function

  • Adaptive changes in signaling efficiency that may counteract therapeutic approaches

  • Potential off-target effects on mitochondrial function in non-neuronal tissues

Addressing these challenges requires continued research into CHRM1 biology and development of increasingly specific tools to target this receptor and its downstream pathways .